首页> 外文期刊>Journal of drugs in dermatology: JDD >Two Randomized, Double-Blind, Split-Face Studies to Compare the Irritation Potential of Two Topical Acne Fixed Combinations Over a 21-Day Treatment Period
【24h】

Two Randomized, Double-Blind, Split-Face Studies to Compare the Irritation Potential of Two Topical Acne Fixed Combinations Over a 21-Day Treatment Period

机译:两项随机,双盲,分脸研究,比较两种局部痤疮固定组合在21天治疗期内的刺激潜力

获取原文
获取原文并翻译 | 示例
           

摘要

Topical therapy of acne vulgaris (acne) is very common, however cutaneous tolerability can influence patient adherence, and concerns about skin irritation have lead to a number of comparative split-face studies. Advances in formulation technology have provided new fixed combinations with lower concentrations of potentially irritating ingredients without compromising efficacy. These developments now afford the opportunity to formulate fixed combinations with higher concentrations of active ingredients that may provide the greater efficacy needed in more severe disease with good tolerability. Here, we compare the tolerability of two such developments, clindamycin-BP 3.75% gel and adapalene 0.3%-BP 2.5% gel, in healthy volunteers with no apparent facial redness or dryness over 21-days, using a split-face methodology. Clindamycin-BP 3.75% gel was more tolerable than adapalene 0.3%-BP 2.5% gel over the duration of the two studies, with statistically significant differences in cumulative change from baseline starting as early as day 4 (stinging), day 5 (erythema, dryness, and scaling), day 6 (burning), and day 8 (itching); and in composite irritation index (stinging, erythema, dryness, scaling, burning, and itching) from day 4. Transepidermal water loss was less with clindamycin-BP 3.75% gel (statistically significant from day 8). Adverse events were twice as common with adapalene 0.3%-BP 2.5% gel.
机译:寻常性痤疮(痤疮)的局部治疗非常普遍,但是皮肤耐受性会影响患者的依从性,并且对皮肤刺激性的担忧已导致进行了许多对比研究。配方技术的进步提供了具有较低浓度的潜在刺激成分的新型固定组合,而不会影响功效。现在,这些进展提供了配制具有更高浓度活性成分的固定组合的机会,这些组合可以提供对更严重疾病具有良好耐受性所需的更大功效。在这里,我们使用分脸方法,比较了21天没有明显面部发红或干燥的健康志愿者中,两种开发的耐受性,克林霉素-BP 3.75%凝胶和阿达帕林0.3%-BP 2.5%凝胶。在两项研究期间,克林霉素-BP 3.75%凝胶比阿达帕林0.3%-BP 2.5%凝胶耐受性更高,最早从第4天(刺痛),第5天(红斑,干燥和结垢),第6天(燃烧)和第8天(痒);从第4天起,其综合刺激指数(刺痛,红斑,干燥,结垢,灼热和瘙痒)从第4天起。使用克林霉素BP 3.75%凝胶时,表皮水分流失较少。不良事件的发生率是阿达帕林0.3%-BP 2.5%凝胶的两倍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号